Biomea Fusion Inc
NASDAQ:BMEA

Watchlist Manager
Biomea Fusion Inc Logo
Biomea Fusion Inc
NASDAQ:BMEA
Watchlist
Price: 1.26 USD -1.56% Market Closed
Market Cap: 89.1m USD

Biomea Fusion Inc
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Biomea Fusion Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Biomea Fusion Inc
NASDAQ:BMEA
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Non-Reccuring Items
-$10.7B
CAGR 3-Years
-72%
CAGR 5-Years
-60%
CAGR 10-Years
-27%
Gilead Sciences Inc
NASDAQ:GILD
Non-Reccuring Items
-$843m
CAGR 3-Years
38%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Non-Reccuring Items
-$3.2B
CAGR 3-Years
-87%
CAGR 5-Years
N/A
CAGR 10-Years
-35%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Non-Reccuring Items
-$543m
CAGR 3-Years
-74%
CAGR 5-Years
N/A
CAGR 10-Years
-60%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Non-Reccuring Items
-$245.5m
CAGR 3-Years
26%
CAGR 5-Years
-10%
CAGR 10-Years
-20%
No Stocks Found

Biomea Fusion Inc
Glance View

Market Cap
89.1m USD
Industry
Biotechnology

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California and currently employs 51 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The firm has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical irreversible programs for the treatment of select cancers.

BMEA Intrinsic Value
0.82 USD
Overvaluation 35%
Intrinsic Value
Price

See Also

Back to Top